Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2026 –2033 | |
|
|
USD 29.33 Million |
| USD 39.22 Million | |
| % | |
|
Global Middle East and Africa Needle Biopsy Market Segmentation, By Needle Type (Trephine Biopsy Needles, Klima Sternal Needle, Salah Needle Aspiration Needle, Jamshidi Needle and Others), Ergonomics (Sharp, Blunt, Quincke, Chiba, Franseen and Others), Procedure (Fine- Needle Aspiration Biopsy, Core Needle Biopsy, Vacuum-Assisted Biopsy, and Image-Guided Biopsy), Sample Site (Muscles, Bones and Other Organs), Utility (Disposable and Reusable), Application (Tumor, Infection, Inflammation and Others), End User (Hospitals, Diagnostic Centers, Biopsy Labs, Ambulatory Surgical Centers, Academic and Research Organizations, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2033
Get Exclusive Sample Copy of this Report Here
|
Attributes
|
Middle East and Africa Needle Biopsy Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
Middle East and Africa
|
|
Key Market Players
|
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
“Advancements in Image-Guided and Robotic Biopsy Systems”
Driver
“Increasing Demand Due to Rising Cancer Incidence and Diagnostic Awareness”
Restraint/Challenge
“High Equipment Costs and Limited Skilled Workforce”
The market is segmented on the basis of needle type, ergonomics, procedure, sample site, utility, application, end user, and distribution channel.
On the basis of needle type, the MEA needle biopsy market is segmented into trephine biopsy needles, klima sternal needle, salah needle aspiration needle, jamshidi needle, and others. The Trephine Biopsy Needles segment dominated the market in 2025, owing to their widespread use in bone marrow sampling and high accuracy for hematological and oncological diagnoses. Hospitals and diagnostic centers prefer trephine needles due to their reliability in obtaining core tissue samples, minimal complications, and compatibility with automated biopsy devices. In addition, their standardized design allows ease of use by clinicians across different hospital departments. The segment’s dominance is supported by growing hematology and oncology patient volumes in countries such as Saudi Arabia, UAE, and Egypt. Trephine needles are also favored for their durability and consistent sample quality, making them a trusted choice for repeat procedures.
The Jamshidi Needle segment is expected to witness the fastest growth during the forecast period, driven by increasing adoption in chronic disease diagnostics and hematological procedures. Jamshidi needles offer improved patient comfort and efficient tissue sampling, which is boosting their usage in private hospitals and specialized diagnostic centers. Growing awareness among clinicians about minimally invasive procedures and patient safety is further contributing to this segment’s rapid growth. The rising use of Jamshidi needles in advanced image-guided procedures is expected to accelerate their adoption across MEA.
On the basis of ergonomics, the market is segmented into sharp, blunt, quincke, chiba, franseen, and others. The Sharp segment dominated the market owing to its precision and efficiency in obtaining clean tissue samples across multiple sample sites. Sharp needles are widely preferred in hospitals and diagnostic centers due to their ability to reduce procedural time, lower patient discomfort, and improve diagnostic accuracy. The segment benefits from strong clinician preference, especially for image-guided biopsies, and continued innovation in needle coatings and tip design. Sharp needles are particularly dominant in bone and muscle biopsies where accuracy is critical. Hospitals in GCC countries continue to adopt sharp needles as standard practice in oncology departments.
The Franseen segment is expected to witness the fastest growth during the forecast period, owing to its unique multi-faceted tip design, which provides larger tissue samples with minimal trauma. The growing use of Franseen needles in tumor diagnostics, particularly in oncology centers in Saudi Arabia and UAE, is driving adoption. Their compatibility with core and image-guided biopsy procedures further supports market expansion. Rising clinician awareness of better tissue yield and improved histopathology outcomes is fueling rapid growth for Franseen needles.
On the basis of procedure, the market is segmented into Fine-Needle Aspiration Biopsy (FNAB), Core Needle Biopsy (CNB), Vacuum-Assisted Biopsy (VAB), and Image-Guided Biopsy. The Core Needle Biopsy segment dominated the market in 2025 with a market share of 52.6% due to its higher diagnostic accuracy compared to FNAB, making it the preferred choice for tumor and organ biopsy procedures. Hospitals and oncology centers in Saudi Arabia, UAE, and Egypt extensively utilize CNB for breast, liver, and prostate cancer diagnostics. Clinicians value CNB for the ability to obtain sufficient tissue for histopathology and molecular testing. Core needle biopsy provides reliable results with fewer repeat procedures, contributing to efficiency in healthcare facilities. It is also widely compatible with image-guided modalities, supporting its dominance across MEA hospitals.
The Image-Guided Biopsy segment is expected to witness the fastest growth during the forecast period, driven by increasing adoption of ultrasound, CT, and MRI-guided procedures across MEA hospitals. Growing cancer incidence and the need for precise sampling in small or deep-seated lesions are key factors contributing to the segment’s rapid growth. Technological innovations in real-time imaging guidance and robotic assistance further accelerate adoption. Urban hospitals and private diagnostic centers are increasingly investing in image-guided systems to reduce procedure time and enhance accuracy.
On the basis of sample site, the market is segmented into muscles, bones, and other organs. The Bones segment dominated the market in 2025, primarily due to the high demand for bone marrow biopsies in oncology and hematology diagnostics. Bone biopsies are standard procedures for leukemia, lymphoma, and multiple myeloma, which are increasingly diagnosed in MEA countries. Hospitals favor this segment for its well-established procedural protocols and clinician familiarity. Bones segment dominance is also reinforced by the availability of specialized needles designed for bone tissue sampling. Saudi Arabia, UAE, and Egypt lead the adoption of bone biopsy procedures due to advanced healthcare infrastructure. The high clinical accuracy and low complication rates of bone biopsies contribute to their widespread use.
The Other Organs segment is expected to witness the fastest growth, during the forecast period, driven by the rising prevalence of liver, breast, kidney, and prostate cancers in MEA. The demand for minimally invasive organ-specific biopsies in hospitals and diagnostic centers is increasing, fueled by the need for accurate histopathological diagnosis and targeted treatment planning. Improved imaging guidance and robotic assistance are making biopsies of other organs safer and more precise. Rising patient preference for outpatient procedures also contributes to the segment’s growth. Adoption is strongest in urban hospitals with advanced oncology departments.
On the basis of utility, the market is segmented into disposable and reusable. The Disposable segment dominated the market in 2025, supported by increasing infection control awareness and stringent hospital hygiene standards. Disposable needles minimize cross-contamination, reduce sterilization requirements, and provide convenience for high-volume diagnostic centers. Adoption is particularly strong in Saudi Arabia, UAE, and Egypt where hospitals follow strict infection prevention protocols. The ease of disposal and single-use convenience also reduces procedural preparation time. Disposable needles are preferred in oncology and high-risk infectious disease diagnostics. Growing regulatory encouragement for single-use devices reinforces dominance.
The Reusable segment is expected to witness the fastest growth during the forecast period, driven by cost-conscious hospitals and clinics in countries such as Kenya and Nigeria. Reusable needles are preferred in certain procedures to optimize procurement budgets, and innovations in sterilization and coating technologies enhance their safety and usability. Hospitals seeking long-term cost efficiency are increasingly investing in reusable needle systems. Training programs on safe reuse procedures are supporting adoption. The growth is further aided by improvements in needle durability and precision.
On the basis of application, the market is segmented into tumor, infection, inflammation, and others. The Tumor segment dominated the market in 2025, due to the rising cancer prevalence across MEA and the need for accurate histopathological diagnosis. Hospitals and oncology centers rely on needle biopsy for breast, liver, prostate, and other tumor assessments, contributing to the segment’s dominance. Growing cancer screening programs in Saudi Arabia, UAE, and Egypt are boosting tumor biopsy volumes. Tumor diagnostics often require high accuracy and core tissue sampling, favoring needle biopsies. Clinician familiarity and patient preference for minimally invasive procedures reinforce dominance.
The Infection segment is expected to witness the fastest growth during the forecast period, owing to increasing diagnostic testing for abscesses, bone infections, and chronic inflammatory diseases. Growing awareness of minimally invasive procedures in infectious disease diagnosis and improved adoption in diagnostic centers are key growth drivers. Hospitals are increasingly performing needle biopsies for infection localization rather than open surgical procedures. The segment benefits from rising investment in rural healthcare facilities. Adoption of image-guided procedures for infection diagnosis also fuels growth.
On the basis of end user, the market is segmented into hospitals, diagnostic centers, biopsy labs, ambulatory surgical centers, academic and research organizations, and others. The Hospitals segment dominated the market in 2025, due to their high patient throughput, advanced infrastructure, and frequent use of needle biopsy for oncology, chronic disease, and routine diagnostics. Hospitals in Saudi Arabia, UAE, and Egypt are leading adopters due to increasing investments in healthcare and cancer screening programs. Hospital dominance is reinforced by their capability to offer image-guided and robotic-assisted biopsy procedures. Hospitals often purchase high-value biopsy systems via direct tender, supporting consistent demand. Skilled clinicians and established pathology labs in hospitals also support the segment’s lead.
The Diagnostic Centers segment is expected to witness the fastest growth during the forecast period, driven by the rising number of specialized diagnostic centers offering minimally invasive biopsy services in urban MEA areas. Adoption is supported by increased patient preference for convenient, outpatient procedures and rapid test results. Diagnostic centers are expanding service portfolios to include image-guided and core needle biopsies. Rising private investment in healthcare is driving center proliferation. Technological upgrades and partnerships with global suppliers accelerate adoption.
On the basis of distribution channel, the market is segmented into direct tender and retail sales. The Direct Tender segment dominated the market in 2025, due to government and large hospital procurement contracts for high-value biopsy systems, including image-guided and robotic-assisted devices. Direct tenders ensure timely delivery, training, and after-sales support. Hospitals in Saudi Arabia, UAE, and Egypt rely on tender-based procurement for large-scale deployments. Long-term service contracts and equipment maintenance agreements reinforce the dominance of direct tenders. Regulatory approvals and government partnerships also favor direct procurement.
The Retail Sales segment is expected to witness the fastest growth during the forecast period, driven by growing demand from private hospitals, clinics, and smaller diagnostic centers seeking smaller-scale procurement of disposable needles and core biopsy kits. The increasing presence of local distributors and e-commerce channels in MEA countries supports this growth. Retail sales allow flexible and faster purchasing options for small facilities. Private diagnostic chains and emerging outpatient centers are fueling retail demand. Convenience, quick availability, and variety of products enhance retail adoption.
The Saudi Arabia Needle Biopsy Market Insight
The Saudi Arabia needle biopsy market captured the largest revenue share of 28.5% in 2025, fueled by rising cancer prevalence, growing investments in healthcare infrastructure, and increased adoption of minimally invasive diagnostic procedures. Hospitals and diagnostic centers are prioritizing accurate and efficient tissue sampling for oncology, infection, and chronic disease diagnostics. The expanding number of specialized oncology centers, combined with government initiatives for early detection and cancer screening, is significantly propelling market growth. Moreover, increasing integration of image-guided and robotic-assisted biopsy systems is enhancing procedural precision and safety. Strong clinician preference and patient awareness are driving wider adoption across both public and private healthcare facilities. The market is also supported by collaborations between global suppliers and local hospitals for advanced biopsy technologies.
UAE Needle Biopsy Market Insight
The UAE needle biopsy market is expected to grow at a substantial CAGR during the forecast period, primarily driven by high healthcare spending, increasing cancer incidence, and the modernization of hospitals with advanced diagnostic technologies. Diagnostic centers and hospitals are investing in core, fine-needle, and image-guided biopsy systems to improve accuracy and patient outcomes. Rising awareness among patients about minimally invasive procedures and faster recovery is fueling demand. Furthermore, the UAE government’s focus on healthcare innovation and medical tourism is supporting the market expansion. Urban hospitals and private diagnostic chains are adopting robotic-assisted and disposable biopsy needles to improve efficiency. The region also benefits from strong availability of skilled clinicians trained in advanced biopsy procedures.
Egypt Needle Biopsy Market Insight
The Egypt needle biopsy market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing cancer prevalence, rising investments in hospital infrastructure, and growing demand for minimally invasive diagnostics. Hospitals and specialized diagnostic centers are increasingly using core and image-guided biopsy procedures for tumors and organ-specific sampling. Patient preference for less invasive procedures with faster recovery supports adoption. Expansion of oncology and diagnostic centers in major cities such as Cairo and Alexandria is further stimulating market growth. Collaboration between local distributors and global biopsy equipment manufacturers is enhancing market accessibility. Rising awareness programs for early detection of cancer and hematological disorders also contribute to growth.
Kenya Needle Biopsy Market Insight
The Kenya needle biopsy market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing access to modern diagnostic technologies and the growing burden of cancer and chronic diseases. Hospitals and diagnostic centers in urban areas are adopting disposable and core needle biopsy systems to improve diagnostic efficiency. Government initiatives promoting cancer screening and early diagnosis are supporting market growth. Limited infrastructure in rural areas is gradually being addressed through mobile diagnostic units and telemedicine-supported biopsy procedures. Training programs for clinicians on image-guided procedures are increasing adoption. The market is benefiting from collaborations between international biopsy device manufacturers and local healthcare providers.
The Middle East and Africa Needle Biopsy industry is primarily led by well-established companies, including:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.